DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the Defense Health Agency’s Lab Joint Working Group has recommended the Company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by TRICARE. TRICARE is the health care program for uniformed service members, retirees and their families around the world.
This coverage recommendation makes the foundational assay of the DMT available to TRICARE’s approximately 9 million members and beneficiaries of the Military Health System. The DMT is the first non-invasive approach to enhance melanoma detection with a greater than 99 percent negative predictive value (NPV).
https://finance.yahoo.com/news/dermtech-announces-foundational-assay-dermtech-133000036.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.